<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName A++V2.4.dtd?>
  <?SourceDTD.Version 2.4?>
  <?ConverterInfo.XSLTName springer2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Eur J Clin Pharmacol</journal-id>
      <journal-title-group>
        <journal-title>European Journal of Clinical Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0031-6970</issn>
      <issn pub-type="epub">1432-1041</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3076563</article-id>
      <article-id pub-id-type="pmid">21305273</article-id>
      <article-id pub-id-type="publisher-id">1000</article-id>
      <article-id pub-id-type="doi">10.1007/s00228-011-1000-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Pharmacogenetics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Effect of the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms on hemodynamic response during dobutamine stress echocardiography</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bana&#x15B;</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>P&#x142;o&#x144;ska</surname>
            <given-names>Edyta</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kurzawski</surname>
            <given-names>Mateusz</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gornik</surname>
            <given-names>Wanda</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Dro&#x17A;dzik</surname>
            <given-names>Marek</given-names>
          </name>
          <address>
            <phone>+48-91-4661589</phone>
            <fax>+48-91-4661600</fax>
            <email>drozdzik@sci.pam.szczecin.pl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland </aff>
        <aff id="Aff2"><label>2</label>Department of Cardiology, Pomeranian Medical University, Szczecin, Poland </aff>
        <aff id="Aff3"><label>3</label>Department of Pharmacology, Pomeranian Medical University, Powstancow Wlkp 72 Str., 70-111 Szczecin, Poland </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>2</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>2</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>67</volume>
      <issue>5</issue>
      <fpage>477</fpage>
      <lpage>482</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>1</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2011</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose</title>
          <p>The aim of this study was to determine an association between the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms and hemodynamic response [heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure] to dobutamine during dobutamine stress echocardiography (DSE).</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>The study involved 144 patients with clinical indications for DSE. The PCR&#x2013;restriction fragment length polymorphism method was used to identify the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Heart rate during DSE increased in all analyzed study groups. Patients with the <italic>ADRB1</italic> 1165CC and 1165CG+GG polymorphisms demonstrated similar HR, including magnitude of response [change in heart rate (&#x394;HR 0&#x2013;30): 42.1&#x2009;&#xB1;&#x2009;17.5 vs. 46.1&#x2009;&#xB1;&#x2009;15.5 bpm, respectively]. HR and &#x394;HR 0&#x2013;30 were comparable in <italic>ADRB1</italic>145AA and 145AG subjects in the course of DSE. SBP and DBP at all stages of DSE were similar in subjects with either polymorphism and did not differentiate patients with the <italic>ADRB1</italic> 145AA polymorphism from those with the <italic>ADRB1</italic> 145AG polymorphism, nor those with the <italic>ADRB1</italic> 1165CC polymorphism from those with the <italic>ADRB1</italic> 1165CG+GG polymorphism. No differences were noted in the magnitude of response, with the increase in SBP and DBP comparable in all genotypes. Similar observations were made in patients (25/144 studied) with atropine requirements during DSE.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms are not associated with the HR, SBP and DBP responses in Polish Caucasian patients requiring diagnostic dobutamine stress echocardiography</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>ADRB1</kwd>
        <kwd>1165C&gt;G and 145A&gt;G polymorphisms</kwd>
        <kwd>Dobutamine stress echocardiography</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>The regulation of cardiovascular response, i.e. heart rate (HR) and blood pressure [both systolic (SBP) and diastolic (DBP)], during physical stress is controlled by both environmental and genetic factors. With respect to the latter, data are available that demonstrate the association of several genes, such as those encoding the beta1-adrenergic receptor [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], G-protein alpha subunit [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] and G-protein beta3 subunit [<xref ref-type="bibr" rid="CR5">5</xref>], with effects on the response rate as measured by HR and BP.</p>
      <p>The beta-adrenoreceptor system plays an important role in the regulation of the human cardiovascular system. Two common polymorphisms have been identified in the beta1-adrenergic receptor gene: <italic>ADRB1</italic> Arg389Gly (rs1801253, c.1165C&gt;G in exon 1) and Ser49Gly (rs1801252, c.145A&gt;G in exon 1). In vitro studies have provided evidence for their functional basis, and these polymorphisms have been implicated in the differential response to &#x3B2;<sub>1</sub>-agonists and antagonists in numerous studies [<xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR10">10</xref>]. However, little information has been published on the effects of <italic>ADRB1</italic> polymorphisms on heart function in stress situations, and the results that have been studied are contradictory, ranging from reports of a significant association to a complete lack of influence [<xref ref-type="bibr" rid="CR12">12</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>].</p>
      <p>Dobutamine is an inotropic synthetic catecholamine commonly used as a diagnostic tool for dobutamine stress echocardiography (DSE). Due to the positive inotropic and chronotropic effects of dobutamine, DSE has become a popular diagnostic tool for the evaluation of coronary artery disease in patients unable to undergo standard exercise stress tests. However, based on clinical observations, there are interpersonal variations in the response to dobutamine or the exercise test in terms of HR (with some patients requiring atropine administration due to an inability to complete the test and achieve target HR) and BP response [<xref ref-type="bibr" rid="CR11">11</xref>&#x2013;<xref ref-type="bibr" rid="CR13">13</xref>]. Polymorphisms in genes involved in regulating heart function may shed light on the observed diversity in heart response to dobutamine. One of the potential candidates is the <italic>ADRB1</italic> gene.</p>
      <p>The aim of this study was to determine an association between <italic>ADRB1</italic> gene polymorphisms and hemodynamic response (namely, HR, SBP and the DBP) to dobutamine during DSE.</p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Subjects</title>
        <p>The study cohort consisted of 144 patients of Caucasian origin (77 women, 67 men; age range 31&#x2013;80 years) with a clinical indication for DSE. Of these 144 patients, 25 required atropine administration during DSE. DSE is standardly indicated for the detection of coronary artery disease in subjects who are unable to undergo standard exercise stress testing. A detailed description of the characteristics of the patients recruited for the study is presented in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. The study protocol was approved by the local ethics committee (Pomeranian Medical University, Szczecin, Poland), and all study participants gave informed written consent.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Patient data</th></tr></thead><tbody><tr><td>Age (years)</td><td>59.3&#x2009;&#xB1;&#x2009;8.8</td></tr><tr><td colspan="2">Sex</td></tr><tr><td>&#xA0;&#xA0;Female</td><td>65 (54.62)</td></tr><tr><td>&#xA0;&#xA0;Male</td><td>54 (45.38)</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>27.8&#x2009;&#xB1;&#x2009;3.85</td></tr><tr><td>Smoking</td><td>19 (15.97)</td></tr><tr><td>Hypertension</td><td>78 (65.55)</td></tr><tr><td>Diabetes</td><td>15 (12.60)</td></tr><tr><td colspan="2">Medication</td></tr><tr><td>&#xA0;&#xA0;Angiotensin-converting enzyme</td><td>55 (46.22)</td></tr><tr><td>&#xA0;&#xA0;Acetylsalicylic acid</td><td>72 (60.50)</td></tr><tr><td>&#xA0;&#xA0;Beta-blockers</td><td>68 (57.14)</td></tr><tr><td>&#xA0;&#xA0;Ca<sup>2+</sup>-blockers</td><td>23 (19.33)</td></tr><tr><td>&#xA0;&#xA0;Statins</td><td>68 (57.14)</td></tr><tr><td>&#xA0;&#xA0;Diuretics</td><td>28 (23.53)</td></tr></tbody></table><table-wrap-foot><p>Patient data are given as the mean &#xB1; standard deviation (SD) or as the number of patients (<italic>n</italic>) with the percentage of patient population given in parenthesis</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title>Clinical assay</title>
        <p>Dobutamine stress echocardiography was performed according to standard guidelines in which the administration of dobutamine is steadily increased over time (from 10, 20, 30 to 40&#xA0;&#x3BC;g/kg/min at 3-min intervals) [<xref ref-type="bibr" rid="CR15">15</xref>]. The HR (based on 12-lead electrocardiogram) and BP were measured at baseline (after a rest period), at the start of the dobutamine infusion period and at the end of each 3-min interval. In patients with atropine requirements, i.e. in subjects who were not able to reach target HR at a dobutamine dose of 30&#xA0;&#x3BC;g/kg/min, the drug was administered in divided doses, beginning at 0.25&#xA0;mg and increasing to 1.0&#xA0;mg. Most patients evaluated reached target HR at a dobutamine level of 30&#xA0;&#x3BC;g/kg/min, which was then taken for all subjects to be the end time-point for analysis. Each subject discontinued beta-blockers and/or calcium channel blockers at least five half-lives of the drug before study onset.</p>
      </sec>
      <sec id="Sec5">
        <title>Genotyping</title>
        <p>Genomic DNA was extracted from samples of peripheral blood leukocytes according to a standard protocol. Genotyping of the <italic>ADRB1</italic> Arg389Gly (rs1801253, c.1165C&gt;G in exon 1) and Ser49Gly (rs1801252, c.145A&gt;G in exon 1) polymorphisms, using a PCR&#x2013;restriction fragment length polymorphism (RFLP) method with <italic>Bsm</italic>FI and <italic>Eco</italic>0109I restriction enzymes, respectively, was performed as described previously [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>Statistical analysis</title>
        <p>Based on allele frequencies, it was expected that the number of <italic>ADRB1</italic> 1165GG and 145GG homozygotes would be low. As such, it was planned a priori that in our analysis <italic>ADRB1</italic> 1165GG and 145GG homozygotes would be combined with <italic>ADRB1</italic> 1165GG and 145GG heterozygotes. Conformity of genotype distributions to the Hardy&#x2013;Weinberg law was assessed using &#x3C7;<sup>2</sup>-test. Categorical baseline characteristics were compared between groups using the Fisher exact test (Statistica ver. 8.0; Statsoft Software, Warsaw, Poland). Numerical variables between groups were evaluated by the Mann&#x2013;Whitney <italic>U</italic> test. A <italic>p</italic> level &lt;0.05 was considered to be statistically significant.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Results</title>
      <p>The patients were stratified into two groups based on the identification of the <italic>ADRB1</italic> 1165C&gt;G or 145A&gt;G polymorphism. No significant differences between the groups were found for the parameters presented in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> (general patient data), namely, age, sex, body mass index (BMI), smoking habits, coexistent cardiovascular diseases and medication. Genotype and allele distributions fit the Hardy&#x2013;Weinberg equilibrium in both study groups. Taking into account the observed genotype frequencies and the standard deviation (SD), for 119 patients this study has a &gt;80% power to detect differences in SBP, DBP and HR if they exceed 9.5, 5.8 and 6.4, respectively, for the Ser49Gly polymorphism and 8.5, 5.0 and 5.5, respectively, for theArg389Gly polymorphism. For differences between starting parameters and those observed after the administration of 30&#xA0;&#x3BC;g of dobutamine, our study has a &gt;80% power when the difference in the mean values between genotype-stratified patients would be &gt;11.6 (&#x394;SPB), 4.9 (&#x394;DBP) and 10.4 (&#x394;HR) for the Ser49Gly polymorphism and 10.0, 4.3 and 9.1, respectively, for the Arg389Gly polymorphism.</p>
      <sec id="Sec8">
        <title>Resting hemodynamics</title>
        <p>All resting hemodynamic parameters were similar in <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G carriers. Patients with <italic>ADRB1</italic> 1165CC and 1165CG+GG as well as the 145AA and 145AG genotypes were characterized by comparable resting HR, SBP and DBP (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Resting systolic blood pressure, diastolic blood pressure and heart rate</p></caption><table frame="hsides" rules="groups"><thead><tr><th><italic>ADRB1</italic> polymorphism</th><th>Genotype</th><th>Mean SBP (mmHg)</th><th><italic>p</italic><sup>a</sup></th><th>Mean DBP (mmHg)</th><th><italic>p</italic><sup>a</sup></th><th>Mean HR (bpm)</th><th><italic>p</italic><sup>a</sup></th></tr></thead><tbody><tr><td rowspan="2">145A&gt;G</td><td>AA (<italic>n</italic>&#x2009;=&#x2009;90)</td><td>133.4&#x2009;&#xB1;&#x2009;15.7</td><td rowspan="2">0.948</td><td>83.4&#x2009;&#xB1;&#x2009;9.8</td><td rowspan="2">0.655</td><td>70.5&#x2009;&#xB1;&#x2009;10.7</td><td rowspan="2">0.104</td></tr><tr><td>AG (<italic>n</italic>&#x2009;=&#x2009;29)</td><td>133.6&#x2009;&#xB1;&#x2009;16.4</td><td>82.8&#x2009;&#xB1;&#x2009;8.4</td><td>66.9&#x2009;&#xB1;&#x2009;9.8</td></tr><tr><td rowspan="2">1165C&gt;G</td><td>CC (<italic>n</italic>&#x2009;=&#x2009;67)</td><td>132.4&#x2009;&#xB1;&#x2009;15.2</td><td rowspan="2">0.516</td><td>83.3&#x2009;&#xB1;&#x2009;9.3</td><td rowspan="2">0.719</td><td>69.3&#x2009;&#xB1;&#x2009;10.1</td><td rowspan="2">0.800</td></tr><tr><td>GC+GG (<italic>n</italic>&#x2009;=&#x2009;52)</td><td>134.7&#x2009;&#xB1;&#x2009;16.7</td><td>83.3&#x2009;&#xB1;&#x2009;9.8</td><td>70.0&#x2009;&#xB1;&#x2009;11.2</td></tr></tbody></table><table-wrap-foot><p>All values are given as the mean &#xB1; SD</p><p>SBP, Resting systolic blood pressure, DBP, resting diastolic BP; HR, heart rate</p><p><sup>a</sup>Significance was determined using the Mann&#x2013;Whitney test <italic>U</italic> test</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec9">
        <title>HR, SBP and DBP response during DSE</title>
        <p>The heart rate during DSE increased in all analyzed groups of the study. Patients with the <italic>ADRB1</italic> 1165CC or 1165CG+GG polymorphism had similar HR, including magnitude of response (&#x394;HR 0&#x2013;30: 42.1&#x2009;&#xB1;&#x2009;17.5 vs. 46.1&#x2009;&#xB1;&#x2009;15.5 bpm, respectively). Likewise, the HR in the course of DSE and &#x394;HR 0&#x2013;30 were comparable in <italic>ADRB1</italic>145AA and 145AG subjects (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table&#xA0;3</label><caption><p>Heart rate and increase in heart rate (&#x2206;HR) at consecutive stages of DSE</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Dobutamine dose (&#x3BC;g/kg/min)<sup>a</sup></th><th colspan="2"><italic>ADRB1</italic> 145A&gt;G</th><th rowspan="2"><italic>p</italic><sup>b</sup></th><th colspan="2"><italic>ADRB1</italic> 1165C&gt;G</th><th rowspan="2"><italic>p</italic><sup>b</sup></th></tr><tr><th>AA (<italic>n</italic>&#x2009;=&#x2009;90)</th><th>AG (<italic>n</italic>&#x2009;=&#x2009;29)</th><th>CC (<italic>n</italic>&#x2009;=&#x2009;67)</th><th>GC+GG (<italic>n</italic>&#x2009;=&#x2009;52)</th></tr></thead><tbody><tr><td>HR 0</td><td>70.5&#x2009;&#xB1;&#x2009;10.7</td><td>66.9&#x2009;&#xB1;&#x2009;9.8</td><td>0.104</td><td>69.3&#x2009;&#xB1;&#x2009;10.1</td><td>70.0&#x2009;&#xB1;&#x2009;11.2</td><td>0.800</td></tr><tr><td>HR 10</td><td>75.7&#x2009;&#xB1;&#x2009;10.6</td><td>71.7&#x2009;&#xB1;&#x2009;9.2</td><td>0.079</td><td>74.8&#x2009;&#xB1;&#x2009;10.3</td><td>74.7&#x2009;&#xB1;&#x2009;10.6</td><td>0.735</td></tr><tr><td>HR 20</td><td>92.7&#x2009;&#xB1;&#x2009;17.3</td><td>89.3&#x2009;&#xB1;&#x2009;10.5</td><td>0.347</td><td>92.9&#x2009;&#xB1;&#x2009;19.5</td><td>90.5&#x2009;&#xB1;&#x2009;16.2</td><td>0.456</td></tr><tr><td>HR 30</td><td>112.6&#x2009;&#xB1;&#x2009;19.9</td><td>113.0&#x2009;&#xB1;&#x2009;18.3</td><td>0.988</td><td>114.5&#x2009;&#xB1;&#x2009;19.4</td><td>110.5&#x2009;&#xB1;&#x2009;19.5</td><td>0.286</td></tr><tr><td>&#x394;HR 0&#x2013;30</td><td>42.1&#x2009;&#xB1;&#x2009;17.5</td><td>46.1&#x2009;&#xB1;&#x2009;15.5</td><td>0.211</td><td>45.1&#x2009;&#xB1;&#x2009;18.1</td><td>40.5&#x2009;&#xB1;&#x2009;15.4</td><td>0.193</td></tr></tbody></table><table-wrap-foot><p>All values are given as the mean &#xB1; SD</p><p>DSE, Dobutamine stress echocardiography</p><p><sup>a</sup>HR 0, 10, 20, 30, Heart rate at baseline and at 10, 20, 30 &#x3BC;g/kg/min dobutamine, respectively; &#x394;HR, Change in heart rate from baseline and the end of the experiment</p><p><sup>b</sup>Significance was determined using the Mann&#x2013;Whitney test <italic>U</italic> test</p></table-wrap-foot></table-wrap></p>
        <p>The SBP at all stages of DSE was similar in patients with either polymorphism and did not differentiate <italic>ADRB1</italic>145AA from 145AG subjects, and <italic>ADRB1</italic> 1165CC from 1165CG+GG cases. Differences were noted in magnitude of response (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab4"><label>Table&#xA0;4</label><caption><p>Systolic blood pressureand its increase (&#x394;SBP) at consecutive stages of DSE</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Dobutamine dose (&#x3BC;g/kg/min)<sup>a</sup></th><th colspan="2"><italic>ADRB1</italic> 145A&gt;G</th><th rowspan="2"><italic>p</italic><sup>b</sup></th><th colspan="2"><italic>ADRB1 </italic>1165C&gt;G</th><th rowspan="2"><italic>p</italic><sup>b</sup></th></tr><tr><th>AA (<italic>n</italic>&#x2009;=&#x2009;90)</th><th>AG (<italic>n</italic>&#x2009;=&#x2009;29)</th><th>CC (<italic>n</italic>&#x2009;=&#x2009;67)</th><th>GC+GG (<italic>n</italic>&#x2009;=&#x2009;52)</th></tr></thead><tbody><tr><td>SBP 0</td><td>133.4&#x2009;&#xB1;&#x2009;15.7</td><td>133.6&#x2009;&#xB1;&#x2009;16.4</td><td>0.948</td><td>132.4&#x2009;&#xB1;&#x2009;15.2</td><td>134.7&#x2009;&#xB1;&#x2009;16.7</td><td>0.516</td></tr><tr><td>SBP 10</td><td>138.5&#x2009;&#xB1;&#x2009;16.0</td><td>138.2 &#xB1;16.9</td><td>0.988</td><td>137.7&#x2009;&#xB1;&#x2009;16.2</td><td>139.3&#x2009;&#xB1;&#x2009;16.3</td><td>0.679</td></tr><tr><td>SBP 20</td><td>146.7&#x2009;&#xB1;&#x2009;19.4</td><td>147.6&#x2009;&#xB1;&#x2009;21.7</td><td>0.861</td><td>146.2&#x2009;&#xB1;&#x2009;20.0</td><td>147.8&#x2009;&#xB1;&#x2009;19.9</td><td>0.796</td></tr><tr><td>SBP 30</td><td>150.5&#x2009;&#xB1;&#x2009;20.2</td><td>150.9&#x2009;&#xB1;&#x2009;27.2</td><td>0.948</td><td>149.6&#x2009;&#xB1;&#x2009;22.2</td><td>151.9&#x2009;&#xB1;&#x2009;21.9</td><td>0.530</td></tr><tr><td>&#x394;SBP 0-30</td><td>17.1&#x2009;&#xB1;&#x2009;16.9</td><td>17.3&#x2009;&#xB1;&#x2009;25.1</td><td>0.719</td><td>17.1&#x2009;&#xB1;&#x2009;20.6</td><td>17.2&#x2009;&#xB1;&#x2009;17.2</td><td>0.755</td></tr></tbody></table><table-wrap-foot><p>All values are given as the mean &#xB1; SD</p><p><sup>a</sup>SBP, 10, 20, 30, Systolic blood pressure at baseline and at 10, 20 and 30 &#x3BC;g/kg/min dobutamine, respectively; &#x394;SBP 0-30, change in systolic blood pressure from baseline to end of experiment</p><p><sup>b</sup>Significance was determined using the Mann&#x2013;Whitney test <italic>U</italic> test</p></table-wrap-foot></table-wrap></p>
        <p>DBP response in the course of DSE was similar in both analyzed polymorphisms of <italic>ADRB1</italic> gene. DBP decreased during DSE at a rate comparable in all analyzed <italic>ADRB1</italic> subgroups. A similar trend was observed for magnitude of DBP response (Table&#xA0;<xref rid="Tab5" ref-type="table">5</xref>).
<table-wrap id="Tab5"><label>Table&#xA0;5</label><caption><p>Diastolic blood pressure and its increase (&#x394;DBP) at consecutive stages of DSE</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Dobutamine dose (&#x3BC;g/kg/min)<sup>a</sup></th><th colspan="2"><italic>ADRB1</italic> 145A&gt;G</th><th rowspan="2"><italic>p</italic><sup>b</sup></th><th colspan="2"><italic>ADRB1</italic> 1165C&gt;G</th><th rowspan="2"><italic>p</italic><sup>b</sup></th></tr><tr><th>AA (<italic>n</italic>&#x2009;=&#x2009;90)</th><th>AG (<italic>n</italic>&#x2009;=&#x2009;29)</th><th>CC (<italic>n</italic>&#x2009;=&#x2009;67)</th><th>GC+GG (<italic>n</italic>&#x2009;=&#x2009;52)</th></tr></thead><tbody><tr><td>DBP 0</td><td>83.4&#x2009;&#xB1;&#x2009;9.8</td><td>82.8&#x2009;&#xB1;&#x2009;8.4</td><td>0.655</td><td>83.3&#x2009;&#xB1;&#x2009;9.3</td><td>83.3&#x2009;&#xB1;&#x2009;9.8</td><td>0.719</td></tr><tr><td>DBP 10</td><td>87.6&#x2009;&#xB1;&#x2009;10.5</td><td>83.5&#x2009;&#xB1;&#x2009;13.7</td><td>0.181</td><td>87.0&#x2009;&#xB1;&#x2009;11.6</td><td>86.2&#x2009;&#xB1;&#x2009;11.3</td><td>0.900</td></tr><tr><td>DBP 20</td><td>84.0&#x2009;&#xB1;&#x2009;9.5</td><td>82.7&#x2009;&#xB1;&#x2009;9.5</td><td>0.319</td><td>83.3&#x2009;&#xB1;&#x2009;10.4</td><td>84.3&#x2009;&#xB1;&#x2009;8.1</td><td>0.573</td></tr><tr><td>DBP 30</td><td>80.8&#x2009;&#xB1;&#x2009;9.0</td><td>79.9&#x2009;&#xB1;&#x2009;11.2</td><td>0.719</td><td>80.1&#x2009;&#xB1;&#x2009;10.6</td><td>81.3&#x2009;&#xB1;&#x2009;8.1</td><td>0.443</td></tr><tr><td>&#x394;DBP 0-30</td><td>&#x2212;2.6&#x2009;&#xB1;&#x2009;7.9</td><td>&#x2212;2.9&#x2009;&#xB1;&#x2009;8.9</td><td>0.890</td><td>&#x2212;3.2&#x2009;&#xB1;&#x2009;7.9</td><td>-1.9&#x2009;&#xB1;&#x2009;8.4</td><td>0.664</td></tr></tbody></table><table-wrap-foot><p>All values are given as the mean &#xB1; SD</p><p><sup>a</sup>DBP 10, 20, 30, Diastolic blood pressure at baseline and at 10, 20 and 30 &#x3BC;g/kg/min dobutamine, respectively; &#x394;DBP 0-30, change in Diastolic blood pressure from baseline to end of experiment</p><p><sup>b</sup>Significance was determined using the Mann&#x2013;Whitney test <italic>U</italic> test</p></table-wrap-foot></table-wrap></p>
        <p>Similarly to patients not requiring atropine, subjects with atropine demands were characterized by similar HR, SBP, DBP and magnitude of hemodynamic response in all analyzed groups of <italic>ADRB1</italic> polymorphisms (except for some isolated SBP measurements) (Table&#xA0;<xref rid="Tab6" ref-type="table">6</xref>).
<table-wrap id="Tab6"><label>Table&#xA0;6</label><caption><p>Heart rate, SBP, DBP and increase in heart rate (&#x394;HR), SBP (&#x394;SBP) and DBP (&#x394;DBP) at consecutive stages of DSE in patients requiring atropine administration</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Dobutamine dose (&#x3BC;g/kg/min)</th><th colspan="2"><italic>ADRB1</italic> 145A&gt;G</th><th rowspan="2">p</th><th colspan="2"><italic>ADRB1</italic> 1165C&gt;G</th><th rowspan="2"><italic>p</italic><sup>a</sup></th></tr><tr><th>AA (<italic>n</italic>&#x2009;=&#x2009;17)</th><th>AG+GG (<italic>n</italic>&#x2009;=&#x2009;8)</th><th>CC (<italic>n</italic>&#x2009;=&#x2009;16)</th><th>GC+GG (<italic>n</italic>&#x2009;=&#x2009;9)</th></tr></thead><tbody><tr><td>HR 0</td><td>69.1&#x2009;&#xB1;&#x2009;11.9</td><td>65.3 &#xB1;10.0</td><td>0.406</td><td>68.4&#x2009;&#xB1;&#x2009;12.1</td><td>67.0&#x2009;&#xB1;&#x2009;10.2</td><td>0.760</td></tr><tr><td>HR 10</td><td>71.5&#x2009;&#xB1;&#x2009;12.0</td><td>72.6 &#xB1;12.7</td><td>0.887</td><td>74.3&#x2009;&#xB1;&#x2009;12.9</td><td>67.7&#x2009;&#xB1;&#x2009;9.3</td><td>0.419</td></tr><tr><td>HR 20</td><td>76.6&#x2009;&#xB1;&#x2009;15.4</td><td>82.5 &#xB1;11.7</td><td>0.215</td><td>82.7&#x2009;&#xB1;&#x2009;15.7</td><td>71.0&#x2009;&#xB1;&#x2009;7.7</td><td>0.074</td></tr><tr><td>HR 30</td><td>108.6&#x2009;&#xB1;&#x2009;23.4</td><td>117.3&#x2009;&#xB1;&#x2009;22.4</td><td>0.406</td><td>117.1&#x2009;&#xB1;&#x2009;21.5</td><td>101.1&#x2009;&#xB1;&#x2009;23.1</td><td>0.108</td></tr><tr><td>&#x394;HR 0-30</td><td>39.5&#x2009;&#xB1;&#x2009;23.7</td><td>52.0 &#xB1;23.2</td><td>0.215</td><td>48.8&#x2009;&#xB1;&#x2009;23.6</td><td>34.1&#x2009;&#xB1;&#x2009;22.4</td><td>0.121</td></tr><tr><td>SBP 0</td><td>79.1&#x2009;&#xB1;&#x2009;8.1</td><td>79.6&#x2009;&#xB1;&#x2009;11.5</td><td>0.977</td><td>122.4&#x2009;&#xB1;&#x2009;14.0</td><td>130.4&#x2009;&#xB1;&#x2009;17.3</td><td>0.276</td></tr><tr><td>SBP 10</td><td>79.4&#x2009;&#xB1;&#x2009;8.4</td><td>76.4&#x2009;&#xB1;&#x2009;12.9</td><td>0.754</td><td>123.7&#x2009;&#xB1;&#x2009;16.8</td><td>135.8&#x2009;&#xB1;&#x2009;11.8</td><td>0.049</td></tr><tr><td>SBP 20</td><td>76.9&#x2009;&#xB1;&#x2009;10.6</td><td>76.1&#x2009;&#xB1;&#x2009;13.1</td><td>0.842</td><td>131.9&#x2009;&#xB1;&#x2009;15.7</td><td>129.6&#x2009;&#xB1;&#x2009;16.3</td><td>1.000</td></tr><tr><td>SBP 30</td><td>80.6&#x2009;&#xB1;&#x2009;10.1</td><td>81.0&#x2009;&#xB1;&#x2009;10.2</td><td>0.842</td><td>142.0&#x2009;&#xB1;&#x2009;17.7</td><td>135.0&#x2009;&#xB1;&#x2009;15.6</td><td>0.388</td></tr><tr><td>&#x394;SBP 0-30</td><td>13.4&#x2009;&#xB1;&#x2009;17.4</td><td>15.9&#x2009;&#xB1;&#x2009;18.7</td><td>0.932</td><td>19.6&#x2009;&#xB1;&#x2009;16.5</td><td>4.6&#x2009;&#xB1;&#x2009;15.6</td><td>0.043</td></tr><tr><td>DBP 0</td><td>79.1&#x2009;&#xB1;&#x2009;8.1</td><td>79.6&#x2009;&#xB1;&#x2009;11.5</td><td>0.977</td><td>78.1&#x2009;&#xB1;&#x2009;10.1</td><td>81.2&#x2009;&#xB1;&#x2009;6.9</td><td>0.419</td></tr><tr><td>DBP 10</td><td>79.4&#x2009;&#xB1;&#x2009;8.4</td><td>76.4&#x2009;&#xB1;&#x2009;12.9</td><td>0.754</td><td>76.9&#x2009;&#xB1;&#x2009;10.7</td><td>81.1&#x2009;&#xB1;&#x2009;8.0</td><td>0.251</td></tr><tr><td>DBP 20</td><td>76.9&#x2009;&#xB1;&#x2009;10.6</td><td>76.1&#x2009;&#xB1;&#x2009;13.1</td><td>0.842</td><td>76.9&#x2009;&#xB1;&#x2009;12.0</td><td>76.1&#x2009;&#xB1;&#x2009;10.1</td><td>0.677</td></tr><tr><td>DBP 30</td><td>80.6&#x2009;&#xB1;&#x2009;10.1</td><td>81.0&#x2009;&#xB1;&#x2009;10.2</td><td>0.842</td><td>79.5&#x2009;&#xB1;&#x2009;11.0</td><td>82.9&#x2009;&#xB1;&#x2009;7.6</td><td>0.452</td></tr><tr><td>&#x394;DBP 0-30</td><td>1.5&#x2009;&#xB1;&#x2009;8.7</td><td>1.4&#x2009;&#xB1;&#x2009;15.4</td><td>0.511</td><td>1.4&#x2009;&#xB1;&#x2009;12.1</td><td>1.7&#x2009;&#xB1;&#x2009;9.0</td><td>0.846</td></tr></tbody></table><table-wrap-foot><p>All values are given as the mean &#xB1; SD</p><p><sup>a</sup>Significance was determined using the Mann&#x2013;Whitney test <italic>U</italic> test</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Discussion</title>
      <p>The aim of this study was to define the role of the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms in interindividual variability to dobutamine response during DSE (among patients with clinical indication for the test). The data currently available are not consistent regarding the associations of <italic>ADRB1</italic> single nucleotide polymorphisms with hemodynamic response during stress situations, including DSE. Our results did not demonstrate a significant association between the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms and three parameters of hemodynamic response during DSE, i.e. HR, SBP and DBP, or with the magnitude of response of these parameters, both in patients with and without atropine requirements within the constraints of the standard DSE protocol. These observations are in keeping with the data reported by Aquilante et al. [<xref ref-type="bibr" rid="CR2">2</xref>] who did not demonstrate any influence of the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms on HR, SBP and DBP response in American Caucasians during DSE, which had been clinically indicated (with four drug half-lives of beta-adrenolytics withdrawal before the study onset). Similar observations were also reported by Kindermann et al. [<xref ref-type="bibr" rid="CR17">17</xref>], who studied the effect of dobutamine administered in the DSE protocol on HR, SBP and contractility parameters. These authors did not note any association between the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms and HR and SBP, although the <italic>ADRB1</italic> 1165C&gt;G polymorphism was associated with other hemodynamic parameters (systemic vascular resistance, ventricular end-systolic meridional wall stress). The <italic>ADRB1</italic> 145A&gt;G polymorphism had no effect on any of the measured parameters. The findings of our study and those of Aquilante et al. [<xref ref-type="bibr" rid="CR2">2</xref>] and Kindermann et al. [<xref ref-type="bibr" rid="CR17">17</xref>] are in contrast to data on a German population presented by La Rosee et al. [<xref ref-type="bibr" rid="CR14">14</xref>]. These authors evaluated the influence of the <italic>ADRB1</italic> 1165C&gt;G polymorphism on hemodynamic response in healthy volunteers premedicated with atropine in order to block the parasympathetic system. They found a significant association between the <italic>ADRB1</italic> polymorphism and SBP, with <italic>ADRB1</italic> 1165CC homozygotes having a greater increase in the SBP response to dobutamine during DSE than carriers of the 1165GG polymorphism. The differences between our findings and those of Aquilante et al. [<xref ref-type="bibr" rid="CR2">2</xref>] and La Rosee et al. [<xref ref-type="bibr" rid="CR14">14</xref>] may possibly be attributed to the different populations studied: those in our study and that of Aquilante et al. [<xref ref-type="bibr" rid="CR2">2</xref>] were recruited among patients with a clinical indication for DSE, while La Rosee et al. analyzed healthy volunteers [<xref ref-type="bibr" rid="CR14">14</xref>]. However, the negative results reported by Kindermann et al. [<xref ref-type="bibr" rid="CR17">17</xref>] were also from a healthy population. Another factor which should be considered is the parasympathetic system blockade introduced by La Rosee et al. [<xref ref-type="bibr" rid="CR14">14</xref>] with atropine administration; this might attenuate the genotype-related response to dobutamine in our patients and those of Aquillante et al. [<xref ref-type="bibr" rid="CR2">2</xref>]. La Rosee et al. administered atropine to healthy volunteers prior to the study and observed effects of the <italic>ADRB1</italic> polymorphism under cholinergic blockade, whereas the patients from our study requiring atropine to complete the DSE were not stratified according <italic>ADRB1</italic> polymorphisms. HR was also not associated with the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms in Finnish study conducted in patients subjected to an exercise test based on clinical indication. In this latter study, an association was noted between <italic>ADRB1</italic> 1165C&gt;G maximal SBP during exercise and SBP changes from rest to maximal [<xref ref-type="bibr" rid="CR13">13</xref>]. A summary of studies conducted on the association of hemodynamic changes during stress with the <italic>ADRB1</italic> polymorphisms is presented in Table&#xA0;<xref rid="Tab7" ref-type="table">7</xref>.
<table-wrap id="Tab7"><label>Table&#xA0;7</label><caption><p>Summary of studies of <italic>ABCB1</italic> polymorphism associations with hemodynamic response</p></caption><table frame="hsides" rules="groups"><thead><tr><th><italic>ADRB1</italic> polymorphisms</th><th>Type of subjects</th><th>Number of subjects</th><th>Type of stress</th><th>Results</th><th>Reference</th></tr></thead><tbody><tr><td>1165C&gt;G 145A&gt;G</td><td>Patients with indications for DSE</td><td>163 (132 Caucasians; 26 Blacks; 7 others</td><td>DSE</td><td>No association between the polymorphisms and HR, SBP, DBP and magnitude of response</td><td>[<xref ref-type="bibr" rid="CR2">2</xref>]</td></tr><tr><td>1165C&gt;G</td><td>Healthy male volunteers premedicated with atropine</td><td>30 Caucasians</td><td>DSE</td><td>Association between the polymorphism and SBP</td><td>[<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td>1165C&gt;G 145A&gt;G</td><td>Patients with indications for exercise test</td><td>890 Caucasians</td><td>Exercise test</td><td>Association between ADRB1 1165C&gt;G maximal SBP during exercise and SBP changes from rest to maximal</td><td>[<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td>1165C&gt;G 145A&gt;G</td><td>Healthy male volunteers</td><td>38 Caucasians</td><td>DSE</td><td>No association between the polymorphisms and HR, SBP</td><td> [<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td>1165C&gt;G 145A&gt;G</td><td>Patients with indications for DSE</td><td>144 Caucasians</td><td>DSE</td><td>No association between the polymorphisms and HR, SBP, DBP and magnitude of response</td><td>Present study</td></tr></tbody></table></table-wrap></p>
      <p>The parameter which was not affected by the <italic>ADRB1</italic> 1165C&gt;G polymorphism in the three studies cited above was HR during DSE. All studies provided evidence that the <italic>ADRB1</italic> polymorphism is not associated with HR response during DSE.</p>
      <p>In summary, the <italic>ADRB1</italic> 1165C&gt;G and 145A&gt;G polymorphisms are not associated with the HR, SBP and DBP response in Polish Caucasian patients undergoing diagnostic dobutamine stress echocardiography.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humma</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Puckett</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>HE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia</article-title>
          <source>Am J Cardiol</source>
          <year>2001</year>
          <volume>88</volume>
          <fpage>1034</fpage>
          <lpage>1037</lpage>
          <pub-id pub-id-type="doi">10.1016/S0002-9149(01)01986-5</pub-id>
          <pub-id pub-id-type="pmid">11704005</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aquilante</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Yarandi</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Cavallari</surname>
              <given-names>LH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography</article-title>
          <source>Pharmacogenomics J</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>408</fpage>
          <lpage>415</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.tpj.6500490</pub-id>
          <pub-id pub-id-type="pmid">18253135</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jia</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hingorani</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association of the G(s)alpha gene with essential hypertension and response to beta-blockade</article-title>
          <source>Hypertension</source>
          <year>1999</year>
          <volume>34</volume>
          <fpage>8</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">10406816</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>ZQ</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>BL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of 393 T&gt;C polymorphism of GNAS1 gene on dobutamine response in Chinese healthy subjects</article-title>
          <source>J Clin Pharmacol</source>
          <year>2009</year>
          <volume>49</volume>
          <fpage>929</fpage>
          <lpage>936</lpage>
          <pub-id pub-id-type="doi">10.1177/0091270009337945</pub-id>
          <pub-id pub-id-type="pmid">19542315</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shioji</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kokubo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mannami</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association between hypertension and the alpha-adducin, beta1-adrenoreceptor, and G-protein beta3 subunit genes in the Japanese population; the Suita study</article-title>
          <source>Hypertens Res</source>
          <year>2004</year>
          <volume>27</volume>
          <fpage>31</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="doi">10.1291/hypres.27.31</pub-id>
          <pub-id pub-id-type="pmid">15055253</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mason</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Liggett</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
          <article-title>A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor</article-title>
          <source>J Biol Chem</source>
          <year>1999</year>
          <volume>274</volume>
          <fpage>12670</fpage>
          <lpage>12674</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.274.18.12670</pub-id>
          <pub-id pub-id-type="pmid">10212248</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rathz</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Liggett</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
          <article-title>Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking</article-title>
          <source>J Cardiovasc Pharmacol</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>155</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1097/00005344-200202000-00001</pub-id>
          <pub-id pub-id-type="pmid">11791000</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Zineh</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Puckett</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>McGorray</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Yarandi</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Pauly</surname>
              <given-names>DF</given-names>
            </name>
          </person-group>
          <article-title>Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>2003</year>
          <volume>74</volume>
          <fpage>44</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1016/S0009-9236(03)00068-7</pub-id>
          <pub-id pub-id-type="pmid">12844134</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>ZQ</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>ZR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>2003</year>
          <volume>74</volume>
          <fpage>372</fpage>
          <lpage>379</lpage>
          <pub-id pub-id-type="doi">10.1016/S0009-9236(03)00224-8</pub-id>
          <pub-id pub-id-type="pmid">14534524</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mialet Perez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rathz</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Petrashevskaya</surname>
              <given-names>NN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure</article-title>
          <source>Nat Med</source>
          <year>2003</year>
          <volume>9</volume>
          <fpage>1300</fpage>
          <lpage>1305</lpage>
          <pub-id pub-id-type="doi">10.1038/nm930</pub-id>
          <pub-id pub-id-type="pmid">14502278</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daly</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Linares</surname>
              <given-names>OA</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Starling</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Supiano</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Dobutamine pharmacokinetics during dobutamine stress echocardiography</article-title>
          <source>Am J Cardiol</source>
          <year>1997</year>
          <volume>79</volume>
          <fpage>1381</fpage>
          <lpage>1386</lpage>
          <pub-id pub-id-type="doi">10.1016/S0002-9149(97)00144-6</pub-id>
          <pub-id pub-id-type="pmid">9165162</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aquilante</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Humma</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Yarandi</surname>
              <given-names>HN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography</article-title>
          <source>Am J Cardiol</source>
          <year>2004</year>
          <volume>94</volume>
          <fpage>535</fpage>
          <lpage>538</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjcard.2004.04.076</pub-id>
          <pub-id pub-id-type="pmid">15325950</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nieminen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lehtim&#xE4;ki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Laiho</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of polymorphisms in beta1-adrenoceptor and alpha-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish cardiovascular study</article-title>
          <source>J Appl Physiol</source>
          <year>2006</year>
          <volume>100</volume>
          <fpage>507</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="doi">10.1152/japplphysiol.00899.2005</pub-id>
          <pub-id pub-id-type="pmid">16210433</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ros&#xE9;e</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Huntgeburth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosenkranz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>B&#xF6;hm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schnabel</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines</article-title>
          <source>Pharmacogenetics</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>711</fpage>
          <lpage>716</lpage>
          <pub-id pub-id-type="doi">10.1097/00008571-200411000-00001</pub-id>
          <pub-id pub-id-type="pmid">15564877</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewandowski</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Bach</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Reduced test time by early identification of patients requiring atropine during dobutamine stress echocardiography</article-title>
          <source>J Am Soc Echocardiogr</source>
          <year>1998</year>
          <volume>11</volume>
          <fpage>236</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1016/S0894-7317(98)70085-9</pub-id>
          <pub-id pub-id-type="pmid">9560747</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryd&#xE9;n</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoffstedt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Eriksson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bringman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Arner</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The Arg 389 Gly beta1-adrenergic receptor gene polymorphism and human fat cell lipolysis</article-title>
          <source>Int J Obes Relat Metab Disord</source>
          <year>2001</year>
          <volume>25</volume>
          <fpage>1599</fpage>
          <lpage>1603</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.ijo.0801815</pub-id>
          <pub-id pub-id-type="pmid">11753577</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="other">Kindermann M, Seeland U, Ruhnke P et al (2010) Functional effects of beta(1)-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without beta-blocker administration. Clin Res Cardiol doi:10.1007/s00392-010-0221-z</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
